ライフサイエンスコーパス: coagulation factor

1 tatic components (platelets, fibrinogen, and coagulation factors).

2 ) results in decreased plasma levels of this coagulation factor.

3 r some of the serine proteases that serve as coagulation factors.

4 and can regulate clearance of platelets and coagulation factors.

5 eceptors, endothelial matrix components, and coagulation factors.

6 vation of function for a number of zebrafish coagulation factors.

7 t imposed by flow-mediated washout of active coagulation factors.

8 C as well as a direct inhibitor of multiple coagulation factors.

9 assessment, including an extensive panel of coagulation factors.

10 ions with histology were found for the other coagulation factors.

11 , including mast cell tryptase and activated coagulation factors.

12 arked angiogenesis with elevation in several coagulation factors.

13 to sustain gamma-carboxylation of many blood coagulation factors.

14 bits serine proteases, including trypsin and coagulation factors.

15 pendence of the INR on the concentrations of coagulation factors.

16 t or eliminate inhibitory antibodies against coagulation factors.

17 a progestin, without increasing the level of coagulation factors.

18 ulation involves activation of platelets and coagulation factors.

19 the catalytic surface for the activation of coagulation factors.

20 ) may be linked to specific mutations in the coagulation factor 12 (FXII) gene (HAE-FXII) or function

21 H may be linked to specific mutations in the coagulation factor 12 (FXII) gene (HAE-FXII) or mutation

22 390-396A) mice appeared to be independent of coagulation factor 13 (FXIII) transglutaminase, as ANIT

23 DIL3 and MFGE8 proteins possess EGF-like and coagulation factor 5/8 (F5/8C) domains, and their 3D str

24 A panel of EGF repeats from human coagulation factor 9 (FA9), mouse Notch1, and Notch2 wer

25 can substitute for proline in the context of coagulation factor 9 EGF repeat for O-glucose transfer,

26 Recipients of continuous coagulation factor administration experienced either sta

27 y expressing 2 reporter proteins (a chimeric coagulation factor and MGP) in HEK293 cells.

28 Vitamin K activates both hepatic coagulation factors and extrahepatic endothelial anticoa

29 d through genome-wide association studies of coagulation factors and fibrin structure/function in hea

30 Plasma levels of all coagulation factors and of the main coagulation inhibito

31 e pharmacokinetic profile of the substituted coagulation factor, and most recently includes novel pro

32 t information on environmental risk factors, coagulation factors, and genetic determinants in patient

33 ic and environmental risk factors, levels of coagulation factors, and other biomarkers for the occurr

34 the hemostatic system, including platelets, coagulation factors, and regulatory proteins.

35 ce for production of pig proteins, including coagulation factors; and (3) these appeared to function

36 ress markers, as well as increased levels of coagulation factors, antedated the loss of insulin secre

37 In the tumor microenvironment, serum coagulation factors are readily extravasated and therefo

38 the increase in PAI-1 levels, whereas other coagulation factors are unaltered.

39 All coagulation screening tests, coagulation factor assays, and platelet function test re

40 trong correlation with lactate clearance and coagulation factors at day 1 and 2 after transplantation

41 Comparison of the pharmacokinetics (PK) of a coagulation factor between groups of patients can be bia

42 brium dissociation constants (K(d)) for each coagulation factor binding to Nanodiscs with unique comp

43 rates that synergy is effective in promoting coagulation factor binding under physiological lipid com

44 aved by matrix metalloproteinases or various coagulation factors but was efficiently cleaved by plasm

45 g of Ad to platelets and vitamin K-dependent coagulation factors, but we found that neither of these

46 duce the total amount of administered plasma coagulation factors by 10%.

47 Mutations in COCH (coagulation factor C homology) are etiologic for the lat

48 Mutations in the COCH (coagulation factor C homology) gene have been attributed

49 Emerging evidence has shown that coagulation factors can directly mediate cancer-associat

50 's GGCX D153G mutant significantly decreased coagulation factor carboxylation and abolished MGP carbo

51 in K concentrations can restore up to 60% of coagulation factor carboxylation but do not ameliorate M

52 he hemostatic system as being regulated by a coagulation factor cascade coupled with platelet activat

53 proteins were clusterin (apoJ), PLTP itself, coagulation factors, complement factors, and apoA-I.

54 ng serine protease/endopeptidase inhibitors, coagulation factors, complement proteins, carbonic anhyd

55 uced rise of factor levels or by infusion of coagulation factor concentrates at the time of delivery.

56 tration of platelet concentrates, plasma, or coagulation factor concentrates should be considered.

57 the hypothesis that thrombin, a blood-borne coagulation factor, contributes to neurovascular injury

58 r XI deficiency is one of the rare inherited coagulation factor deficiencies.

59 e clinical tests commonly used to screen for coagulation-factor deficiencies.

60 N1-MCFD2 (lectin, mannose binding 1/multiple coagulation factor deficiency protein 2) cargo receptor

61 annose-binding protein 1) or MCFD2 (multiple coagulation factor deficiency protein 2), which encode t

62 ered in association with vitamin K-dependent coagulation factor deficiency, an autosomal recessive di

63 stic features of PXE and vitamin K-dependent coagulation factor deficiency.

64 Vitamin K-dependent coagulation factors deficiency is a bleeding disorder ma

65 In coagulation factor-depleted mice hFX also had enhanced a

66 Warfarin pretreatment, to deplete coagulation factors, did not improve tumor uptake signif

67 s study aimed to determine whether levels of coagulation factors differ between patients with neuroim

68 use of the relative infrequency of inherited coagulation factor disorders and the availability of saf

69 electin, and soluble CD40 ligand, as well as coagulation factors, endogenous anticoagulants, and fibr

70 We tested PCC or coagulation factor (F) treatment in CD1 mice made coagul

71 von Willebrand factor multimeric strings and coagulation factor (F) VIII.

72 activated protein C (APC), which inactivates coagulation factors (F) Va and VIIIa.

73 antibodies and mitigate the binding of blood coagulation factor (Factor X) in vitro.

74 Regarding coagulation factors, factor VIII was higher, whereas pro

75 Here we show that the coagulation factor fibrinogen activates the bone morphog

76 ice to directly test the hypothesis that the coagulation factor fibrinogen contributes to colitis-ass

77 effects of exogenous administration of human coagulation factors following pig-to-baboon liver xenotr

78 blood coagulation in vivo and the only blood coagulation factor for which a human genetic defect has

79 is not currently known if ECs produce other coagulation factors for active participation in coagulat

80 that should be implemented to make available coagulation factors for replacement therapy in developin

81 -income countries, the large availability of coagulation factors for replacement therapy of patients

82 The administration of coagulation factors (fresh frozen plasma, prothrombin co

83 o hemophilic mice of cholera toxin B subunit-coagulation factor fusion proteins expressed in chloropl

84 Although both coagulation factors FVII and FX bind the hexon protein o

85 from its distinct role in blood coagulation, coagulation factor FVIIa enhances aggressive behaviors o

86 models of hemostasis, we show that a variant coagulation factor, FXa(I16L), rapidly restores hemostas

87 r (alpha2-PI1-8) that is a substrate for the coagulation factor fXIIIa, to allow its covalent cross-l

88 Thrombin, a serine protease, is a well-known coagulation factor generated during vascular injury and

89 Replacement therapy, providing the missing coagulation factor, has been the mainstay of treatment b

90 After LXT, baboons received no coagulation factors (historical control, n = 1), bolus a

91 terval: 1.42, 2.54; 23 studies, I(2) = 29%), coagulation factor II (thrombin) gene (F2) mutation G202

92 osine-guanine dinucleotide (CpG) site within coagulation factor II (thrombin) receptor-like 3 (F2RL3)

93 ation levels (M values) of cg03636183 in the coagulation factor II (thrombin) receptor-like 3 gene (F

94 ing the thrombin receptors on platelets F2R (coagulation factor II (thrombin) receptor; PAR1) and GP5

95 w that the G protein-coupled receptor (GPCR) coagulation factor II receptor-like 1 (F2rl1, previously

96 Prothrombin, or coagulation factor II, is a multidomain zymogen precurso

97 tients were randomized to 4F-PCC (containing coagulation factors II, VII, IX, and X and proteins C an

98 caused by an inability to synthesize active coagulation factors II, VII, IX, and X, although there i

99 nes related to coagulation and inflammation: coagulation factor III (F3), intercellular adhesion mole

100 P=6.4x10(-52)) was 46.0 kb upstream from F3, coagulation factor III (tissue factor).

101 ating the role of cell-surface receptors for coagulation factors in mouse endotoxemia, we found that

102 Elevation of multiple coagulation factors in Mrc1(-/-)Asgr2(-/-) mice may acco

103 models have implicated an integral role for coagulation factors in neuroinflammatory diseases such a

104 ravascular sites, the expression and role of coagulation factors in NP remain unclear.

105 s study was to investigate the expression of coagulation factors in patients with chronic rhinosinusi

106 udy, we determined antigenic levels of these coagulation factors in primarily pre-event blood samples

107 carboxylase necessary for activation of both coagulation factors in the liver and matrix gla protein,

108 Besides autoimmune mechanisms, coagulation factors, in particular tissue factor and thr

109 anticoagulant warfarin, which depletes other coagulation factors including thrombin, there is a reduc

110 oticeably absent in recipients of continuous coagulation factor infusions compared with the historica

111 udies have suggested noncanonical effects of coagulation factor inhibition that may further modulate

112 In patients who died, coagulation factors involved in the common pathway were

113 cerning coagulation, the reduced activity of coagulation factors is counterbalanced by an increase in

114 se of plasma, platelets, cryoprecipitate and coagulation factor isolates, decrease blood loss in trau

115 at antigenic epitopes derived from an ARF in coagulation factor IX (F9) cDNA can induce CTL reactivit

116 n particular, we target a promoterless human coagulation factor IX (F9) gene to the liver-expressed m

117 d efficient induction of immune tolerance to coagulation factor IX (FIX) by direct intramuscular inje

118 ssion and function, we designed an optimized coagulation factor IX (FIX) variant and used multiple me

119 safety of recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) which,

120 A recombinant fusion protein linking coagulation factor IX (FIX) with human albumin (rIX-FP)

121 onsidering the enzymatic domain of activated coagulation factor IX (FIXa) is homologous to those of t

122 haemophilia B (</=2 IU/dL [</=2%] endogenous coagulation factor IX [FIX] activity).

123 xicity and promote the delivery of the human coagulation factor IX and alpha-galactosidase genes into

124 Oral delivery of coagulation factor IX fused with cholera toxin beta-subu

125 gene on the X chromosome that encodes blood coagulation factor IX, and is predicted to alter RNA spl

126 d expressing a model therapeutic gene, human coagulation Factor IX, in HEK293T cells.

127 er-specific promoter-1 encoding either human coagulation factors IX (hFIX) or X (hFX) into Macaca fas

128 We studied associations of coagulation factors IX through XIII with risk of future

129 of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary

130 complex concentrates; the variability in the coagulation factor levels and contents of prothrombin co

131 This occurs even if coagulation factor levels are normalized, either due to

132 The changes in coagulation factor levels matched the changes in activit

133 Our study demonstrates that coagulation factors may be key mediators in neuroinflamm

134 ypsin but, in contrast to thrombin and other coagulation factors, Na(+) did not stimulate the activit

135 agulants effectively inhibit the activity of coagulation factors of the extrinsic and common pathway

136 Spatial distribution of blood coagulation factors on the surface of procoagulant plate

137 geneity in the surface distribution of major coagulation factors on the surface of procoagulant plate

138 therapy eliminates the need for infusion of coagulation factors (or alternative drugs that promote c

139 d include deficiency of hepatic synthesis of coagulation factors owing to hepatocellular necrosis, cy

140 Although coagulation factors play a role in host defense for "liv

141 nderstanding of the roles that platelets and coagulation factors play in atherothrombosis and review

142 e and protein secretion analysis of our HLCs coagulation factors profile, showing promising results i

143 The genes encoding the coagulation factor proteins were among the first human g

144 The coagulation factor prothrombin has a complex spatial org

145 acids connects kringle-1 to kringle-2 in the coagulation factor prothrombin.

146 cal side effects, while use of fibrinogen or coagulation factors provides only partial mechanisms for

147 Coagulation factor replacement therapy for the X-linked

148 le we concur with the concept of pre-emptive coagulation factor replacement, and initially suggested

149 tion tests are not sensitive to increases in coagulation factors resulting from plasma transfusion.

150 A subsequent search for specified coagulation factors revealed a lamprey system with a sma

151 first drugs designed to inhibit platelets or coagulation factors, such as the antiplatelet clopidogre

152 utant is also activated effectively by other coagulation factors, suggesting that the acidic cluster

153 We conclude that human ECs produce their own coagulation factors that can activate cell surface FX wi

154 Binding of coagulation factors to phosphatidylserine (PS)-exposing

155 despite high-affinity binding of both these coagulation factors to the virus.

156 Affected individuals have normal levels of coagulation factor V (FV) activity, but demonstrate inhi

157 Here, we show that selective expression of coagulation factor V (FV) by resident peritoneal macroph

158 Coagulation factor V (FV) circulates as an inactive proc

159 c donor splice site in a patient with severe coagulation factor V (FV) deficiency and life-threatenin

160 ion, which endocytoses fluorescently labeled coagulation factor V (FV) from the media into alpha-gran

161 Activation of blood coagulation factor V (FV) is a key reaction of hemostasi

162 binase assembly by directly interacting with coagulation factor V (FV), which has been activated by F

163 ed that Gal8 may also interact with platelet coagulation factor V (FV).

164 ed a higher risk of severe preeclampsia with coagulation factor V gene (proaccelerin, labile factor)

165 of the method to a tryptic digest of bovine coagulation factor V resulted in identification of sulfa

166 P=2.4x10(-14)) was 79.7 kb downstream of F5, coagulation factor V.

167 The C domains of coagulation factors V (FV) and VIII (FVIII) are structur

168 protein 2) cargo receptor complex transports coagulation factors V (FV) and VIII (FVIII) from the end

169 s soluble coreceptor MCFD2, LMAN1 transports coagulation factors V (FV) and VIII (FVIII).

170 -derived prothrombin activator homologous to coagulation factors V (FV) and Xa (FXa).

171 a type II (CDAII) and combined deficiency of coagulation factors V and VIII (F5F8D) are the 2 known h

172 lopathy characterized by inactivation of the coagulation factors V and VIII and a derepression of the

173 The discoidin C2 domains of coagulation factors V and VIII are known to interact wit

174 MAD4, INPP5D, and IRAK3; and a disruption of coagulation factors V and VIII.

175 The activation of coagulation factors V and X by Russell's viper venom (RV

176 ies did not involve proteolysis of activated coagulation factors Va and VIIIa.

177 Fibrinogen, coagulation factor VII (FVII), and factor VIII (FVIII) a

178 tamic-acid-rich domain; GLA domain) of human coagulation factor VII as a test model.

179 carboxyglutamic acid domains of procoagulant coagulation factors VII (FVII) and X (FX).

180 Plasma levels of coagulation factors VII (FVII), VIII (FVIII), and von Wi

181 he complex between the trypsin-like protease coagulation factor VIIa (FVIIa) and its cofactor tissue

182 Here we demonstrate that coagulation factor VIIa (FVIIa) elicits TF cytoplasmic d

183 absence of its cofactor tissue factor (TF), coagulation factor VIIa (FVIIa) predominantly exists in

184 The complex of coagulation factor VIIa (FVIIa), a trypsin-like serine p

185 On complex formation with its ligand, coagulation factor VIIa, TF influences protease-activate

186 itiator of the coagulation cascade, mediates coagulation factor VIIa-dependent activation of protease

187 We previously demonstrated that coagulation factor VIII (FVIII) accelerates proteolytic

188 and at physiological pH and ionic strength, coagulation factor VIII (FVIII) accelerates, by a factor

189 philia A and B are caused by deficiencies in coagulation factor VIII (FVIII) and factor IX, respectiv

190 lia A (AHA) is due to autoantibodies against coagulation factor VIII (FVIII) and most often presents

191 Complex formation between coagulation factor VIII (FVIII) and von Willebrand facto

192 The uptake and processing of blood coagulation factor VIII (FVIII) by antigen-presenting ce

193 Human and porcine coagulation factor VIII (fVIII) display a biosynthetic e

194 DLR) was shown to mediate clearance of blood coagulation factor VIII (FVIII) from the circulation.

195 h haemophilia A of all ages with and without coagulation factor VIII (FVIII) inhibitors.

196 neutralizing antibodies (inhibitors) against coagulation factor VIII (FVIII) is the most problematic

197 Development of neutralizing Abs to blood coagulation factor VIII (FVIII) provides a major complic

198 The cellular source of coagulation factor VIII (FVIII) remains controversial.

199 bleeding disorder caused by a deficiency in coagulation factor VIII (fVIII) that affects 1 in 5,000

200 m and also serves as the carrier protein for coagulation factor VIII (FVIII), protecting it from prot

201 We have analyzed expression of coagulation factor VIII (FVIII), the protein deficient i

202 ed bleeding disorder caused by deficiency of coagulation factor VIII (FVIII).

203 development of inhibitor antibodies against coagulation factor VIII (fVIII).

204 Using available genomic sequence data on coagulation factor VIII and predictive models of molecul

205 Using coagulation factor VIII as a model ligand, we now study

206 n immunodeficiency virus type 1 antigens and coagulation factor VIII captured on the cantilever in th

207 Coagulation factor VIII deficient (FVIII(-/-)) mice deve

208 halomyelitis, and antibody responses against coagulation factor VIII in hemophilia A mice, even in an

209 ciated with plasma von Willebrand factor and coagulation factor VIII levels in GWAS, suggesting that

210 ients of nonleukoreduced red blood cells and coagulation factor VIII manufactured from blood of Unite

211 cular injury, we hypothesize that storage of coagulation Factor VIII within platelets may provide a l

212 function, including synthesis and release of coagulation factor VIII, demonstrated that transplanted

213 23/26del) which cannot bind platelets, blood coagulation factor VIII, or collagen, causing VWD throug

214 rs of the 18 tested (interleukin-6, d-dimer, coagulation factor VIII, von Willebrand factor, and homo

215 s also a key determinant in the clearance of coagulation factor VIII.

216 Elevated expression levels of coagulation factors, von Willebrand factor (vWF), and ti

217 Production of several pig coagulation factors was confirmed.

218 Coagulation factors were analyzed using immunostaining,

219 Coagulation factors were analyzed via immunostaining, en

220 s high-level, and in some cases hyperactive, coagulation factors were employed.

221 Assessed coagulation factors were higher in the 4F-PCC group than

222 In four baboons, coagulation factors were measured.

223 s can bind several vitamin K-dependent blood coagulation factors, which contributes to virus sequestr

224 velopment has focused on inhibiting specific coagulation factors, with those targeting thrombin and f

225 species C adenovirus (HAdv) interaction with coagulation factor X (FX) and introduced a mutation that

226 Coagulation factor X (FX) binding to HAdV-5 mediates liv

227 Recently, we demonstrated that coagulation factor X (FX) binds to Ad5-hexon protein at

228 Once in the bloodstream, coagulation factor X (FX) has a pivotal role in determin

229 studies have demonstrated the importance of coagulation factor X (FX) in adenovirus (Ad) serotype 5-

230 s classical role in the coagulation cascade, coagulation factor X (FX) is involved in several major b

231 Serum coagulation factor X (FX) is proposed to play a major ro

232 major Ad5 capsid protein, hexon, binds human coagulation factor X (FX) with an affinity of 229 pM.

233 Adenovirus type 5 (Ad5) specifically binds coagulation factor X (FX), and FX is normally essential

234 r class A member I (SR-AI) as a receptor for coagulation factor X (FX), mediating the formation of an

235 he particles with plasma proteins, including coagulation factor X (FX), which binds specifically to t

236 n between the capsid hexon protein and blood coagulation factor X (FX), whilst penton-alpha(v)integri

237 Ad5 transduction requires blood coagulation factor X (FX); FX binds to the Ad5 capsid he

238 thrombin, and 4 of 10 bound to the activated coagulation factor X (FXa).

239 ymatic domains of thrombin and the activated coagulation factor X (FXa).

240 closed an important gap in our knowledge of coagulation factor X activation by the intrinsic Xase co

241 virions formed unstable complexes with blood coagulation factor X and, because of that, transduced th

242 Down syndrome critical region 1, or hagfish coagulation factor X genes.

243 henotypes of patients with a polymorphism in coagulation factor X.

244 in the present study, we show that activated coagulation factors X (FXa) or VII (FVIIa) directly affe

245 o using a conformationally pliant variant of coagulation factor Xa (FXa(I16L)) rendered partially ina

246 otent tick salivary anticoagulant that binds coagulation factor Xa (FXa) and zymogen FX, with formati

247 Inhibitors of coagulation factor Xa (fXa) have emerged as a new class

248 Direct inhibitors of coagulation factor Xa (FXa) or thrombin are promising or

249 c activation of the protease domain of human coagulation factor Xa into a bacterial trypsin.

250 in Z (PZ), to regulate the function of blood coagulation factor Xa on membrane surfaces.

251 otease inhibitor, enhances the inhibition of coagulation factor Xa, and protein Z-dependent protease

252 o enhance thrombin generation due to binding coagulation factors Xa and Va and accelerating prothromb

253 s as a cofactor-dependent regulator of blood coagulation factors Xa and XIa.

254 Coagulation factor XI (FXI) has become increasingly inte

255 Coagulation factor XI (FXI) is a covalent homodimer cons

256 Activation of coagulation factor XI (FXI) may play a role in hemostasi

257 Coagulation factor XI (FXI) plays an important part in b

258 antisense oligonucleotides (ASOs) targeting coagulation factor XI (FXI), a member of the intrinsic c

259 Since the mechanism of coagulation factor XI (FXI)-dependent thrombus growth re

260 Coagulation factor XI, alpha-1-antichymotrypsin, ficolin

261 No adverse side effects were found for coagulation factor XI, apolipoprotein(a), and SCARA5.

262 ed histo-blood group ABO system transferase, coagulation factor XI, scavenger receptor class A5 (SCAR

263 In the intrinsic pathway of blood coagulation factor XIa (FXIa) activates factor IX (FIX)

264 To select residues in coagulation factor XIa (FXIa) potentially important for

265 ependent fashion, but also directly inhibits coagulation factor XIa.

266 t2a, resides downstream of the gene encoding coagulation factor XII (f12) and was inadvertently modif

267 Inhibition of coagulation factor XII (FXII) activity represents an att

268 For example, mice deficient in coagulation factor XII (fXII) are protected from arteria

269 Coagulation factor XII (FXII) drives production of the i

270 promising solution may be the inhibition of coagulation factor XII (FXII), because its knock-out or

271 partial thromboplastin time measurement for coagulation factor XII (FXII).

272 (T859A, resulting in p.W268R) which encodes coagulation factor XII (FXII).

273 Coagulation factor XII (FXII, Hageman factor, EC = 3.4.2

274 ce of tissue factor and platelets but not on coagulation factor XII and circulating neutrophils.

275 specifically degrade the human glycoprotein coagulation factor XII and not its deglycosylated form,

276 small interfering RNA-mediated depletion of, coagulation factor XII did not alter VT onset, severity,

277 aused by mutation in the C1 inhibitor or the coagulation Factor XII gene.

278 Coagulation factor XII is involved in thrombus formation

279 Tissue factor, coagulation factor XII, platelets, and neutrophils are i

280 nvestigate the involvement of tissue factor, coagulation factor XII, platelets, and neutrophils.

281 In addition, PK can activate coagulation factor XII, the origin of the intrinsic coag

282 activity of platelets with the activation of coagulation factor XII.

283 creased thrombus formation and activation of coagulation factor XII.

284 hesis of selective inhibitors of human blood coagulation factor XIIa and thrombin exhibiting a 1,2,4-

285 cofactor activity in serum was dependent on coagulation factor XIIa, a serine protease known to indu

286 Coagulation factor XIII (FXIII) is a heterotetramer cons

287 Plasma coagulation factor XIII (FXIII) is a transglutaminase th

288 Coagulation factor XIII (FXIII) is a transglutaminase wi

289 Coagulation factor XIII (FXIII) is the main stabilizer o

290 Coagulation Factor XIII (FXIII) plays an important role

291 The activation and regulation of coagulation Factor XIII (FXIII) protein has been the sub

292 n vitro, adhesion depended on fibrinogen and coagulation factor XIII (FXIII), and supraphysiological

293 The activated form of coagulation factor XIII (FXIII-A2B2), FXIII-A*, is a hem

294 ansamidation by both TG2 and activated blood coagulation factor XIII (FXIIIa).

295 Coagulation factor XIII-A has a crucial role in thrombus

296 of several proteins, including kindlin-3 and coagulation factor XIII-A.

297 Activated coagulation factor XIIIa (FXIIIa) covalently cross-links

298 Coagulation factor XIIIa (FXIIIa) is a transglutaminase

299 eover, we observed that the transglutaminase coagulation factor XIIIA (FXIIIA) was one of the most ab

300 tent and specific 66mer peptide inhibitor of coagulation factor XIIIa with six cysteines involved in